302 related articles for article (PubMed ID: 25908121)
1. Characteristics of the use of 3-MMC and other new psychoactive drugs in Slovenia, and the perceived problems experienced by users.
Sande M
Int J Drug Policy; 2016 Jan; 27():65-73. PubMed ID: 25908121
[TBL] [Abstract][Full Text] [Related]
2. Patterns of NPS Use and Risk Reduction in Slovenia.
Sande M; Paš M; Nahtigal K; Šabić S
Subst Use Misuse; 2018 Jul; 53(9):1424-1432. PubMed ID: 29333902
[TBL] [Abstract][Full Text] [Related]
3. The importance of drug checking outside the context of nightlife in Slovenia.
Sande M; Šabić S
Harm Reduct J; 2018 Jan; 15(1):2. PubMed ID: 29329544
[TBL] [Abstract][Full Text] [Related]
4. Patterns and correlates of new psychoactive substance use in a sample of Australian high school students.
Champion KE; Teesson M; Newton NC
Drug Alcohol Rev; 2016 May; 35(3):338-44. PubMed ID: 26194894
[TBL] [Abstract][Full Text] [Related]
5. Do novel psychoactive substances displace established club drugs, supplement them or act as drugs of initiation? The relationship between mephedrone, ecstasy and cocaine.
Moore K; Dargan PI; Wood DM; Measham F
Eur Addict Res; 2013; 19(5):276-82. PubMed ID: 23615495
[TBL] [Abstract][Full Text] [Related]
6. The novel psychoactive substance 3-methylmethcathinone (3-MMC or metaphedrone): A review.
Ferreira B; Dias da Silva D; Carvalho F; de Lourdes Bastos M; Carmo H
Forensic Sci Int; 2019 Feb; 295():54-63. PubMed ID: 30572220
[TBL] [Abstract][Full Text] [Related]
7. Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting.
Palamar JJ; Martins SS; Su MK; Ompad DC
Drug Alcohol Depend; 2015 Nov; 156():112-119. PubMed ID: 26377051
[TBL] [Abstract][Full Text] [Related]
8. I like the old stuff better than the new stuff? Subjective experiences of new psychoactive substances.
Matthews A; Sutherland R; Peacock A; Van Buskirk J; Whittaker E; Burns L; Bruno R
Int J Drug Policy; 2017 Feb; 40():44-49. PubMed ID: 27939599
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of analytically confirmed 3-MMC-related intoxications from the Swedish STRIDA project.
Bäckberg M; Lindeman E; Beck O; Helander A
Clin Toxicol (Phila); 2015 Jan; 53(1):46-53. PubMed ID: 25422862
[TBL] [Abstract][Full Text] [Related]
10. Are government-approved products containing new psychoactive substances perceived to be safer and more socially acceptable than alcohol, tobacco and illegal drugs? Findings from a survey of police arrestees in New Zealand.
Rychert M; Wilkins C; Parker K; Witten K
Drug Alcohol Rev; 2018 Mar; 37(3):406-413. PubMed ID: 29285812
[TBL] [Abstract][Full Text] [Related]
11. Synthetic cathinones: a new public health problem.
Karila L; Megarbane B; Cottencin O; Lejoyeux M
Curr Neuropharmacol; 2015 Jan; 13(1):12-20. PubMed ID: 26074740
[TBL] [Abstract][Full Text] [Related]
12. Determination of cathinones and other stimulant, psychedelic, and dissociative designer drugs in real hair samples.
Salomone A; Gazzilli G; Di Corcia D; Gerace E; Vincenti M
Anal Bioanal Chem; 2016 Mar; 408(8):2035-42. PubMed ID: 26680593
[TBL] [Abstract][Full Text] [Related]
13. Motivations for new psychoactive substance use among regular psychostimulant users in Australia.
Sutherland R; Bruno R; Peacock A; Lenton S; Matthews A; Salom C; Dietze P; Butler K; Burns L; Barratt MJ
Int J Drug Policy; 2017 May; 43():23-32. PubMed ID: 28161577
[TBL] [Abstract][Full Text] [Related]
14. New psychoactive substances: Current health-related practices and challenges in responding to use and harms in Europe.
Pirona A; Bo A; Hedrich D; Ferri M; van Gelder N; Giraudon I; Montanari L; Simon R; Mounteney J
Int J Drug Policy; 2017 Feb; 40():84-92. PubMed ID: 27956184
[TBL] [Abstract][Full Text] [Related]
15. [Cathinones use in Paris].
Batisse A; Grégoire M; Marillier M; Fortias M; Djezzar S
Encephale; 2016 Aug; 42(4):354-60. PubMed ID: 26847479
[TBL] [Abstract][Full Text] [Related]
16. Synthetic psychoactive cathinones: hypothermia and reduced lethality compared to methamphetamine and methylenedioxymethamphetamine.
Muskiewicz DE; Resendiz-Gutierrez F; Issa O; Hall FS
Pharmacol Biochem Behav; 2020 Apr; 191():172871. PubMed ID: 32061662
[TBL] [Abstract][Full Text] [Related]
17. Patterns of use and toxicity of new para-halogenated substituted cathinones: 4-CMC (clephedrone), 4-CEC (4-chloroethcatinone) and 4-BMC (brephedrone).
Grifell M; Ventura M; Carbón X; Quintana P; Galindo L; Palma Á; Fornis I; Gil C; Farre M; Torrens M
Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28657185
[TBL] [Abstract][Full Text] [Related]
18. The diverse reasons for using Novel Psychoactive Substances - A qualitative study of the users' own perspectives.
Soussan C; Andersson M; Kjellgren A
Int J Drug Policy; 2018 Feb; 52():71-78. PubMed ID: 29241144
[TBL] [Abstract][Full Text] [Related]
19. GHB and synthetic cathinones: clinical effects and potential consequences.
Karila L; Reynaud M
Drug Test Anal; 2011 Sep; 3(9):552-9. PubMed ID: 21960540
[TBL] [Abstract][Full Text] [Related]
20. Intended and unintended use of cathinone mixtures.
Guirguis A; Corkery JM; Stair JL; Kirton SB; Zloh M; Schifano F
Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28657191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
